Vivos Therapeutics (VVOS) Common Equity (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Common Equity for 8 consecutive years, with -$4.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 186.97% year-over-year to -$4.0 million in Q2 2026; TTM through Jun 2026 was -$4.0 million, a 186.97% decrease from a year earlier, with the FY2025 full-year figure at -$1.5 million, down 119.49% from the prior year.
• Common Equity was -$4.0 million for Q2 2026 at Vivos Therapeutics, down from -$1.3 million in the prior quarter.
• Over five years, Common Equity peaked at $21.0 million in Q1 2022 and troughed at -$4.0 million in Q2 2026.
• A 5-year average of $4.9 million and a median of $4.5 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 16563.04% in 2024 and plunged 186.97% in 2026, its largest moves.
• Over 5 years, Common Equity stood at $4.8 million in 2022, then sank by 91.44% to $411000.0 in 2023, then surged by 1835.28% to $8.0 million in 2024, then slumped by 119.49% to -$1.5 million in 2025, then tumbled by 157.16% to -$4.0 million in 2026.
• The last three Common Equity figures came in at -$4.0 million (Q2 2026), -$1.3 million (Q1 2026), and -$1.5 million (Q4 2025), per Business Quant data.